{
  "docId": "019de06f-52ef-7226-b4e8-f3f08eb88a26",
  "docSlug": "7c032e01619eda769cbeaf2bcfe382bc",
  "documentTitle": "Pershing Square | Activist Presentation Deck | 110 slides",
  "authorId": "pershing-square",
  "authorName": "Pershing Square Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2014-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 49,
  "pageCount": 110,
  "prevPage": 48,
  "nextPage": 50,
  "slideType": "appendix_disclosure",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de06f-52ef-7226-b4e8-f3f08eb88a26/49",
  "deckHref": "/decks/019de06f-52ef-7226-b4e8-f3f08eb88a26",
  "deckJsonHref": "/decks/019de06f-52ef-7226-b4e8-f3f08eb88a26.json",
  "deckAnchorHref": "/decks/019de06f-52ef-7226-b4e8-f3f08eb88a26#slide-49",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "callout",
      "text": "Valeant is the only major pharmaceutical company that discloses organic growth",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de6ba608-d90f-4474-922e-cd92ad78ca3e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.47
      },
      "kind": "list",
      "text": "Same Store\n1) Including the effect of generic entry\n2) Excluding the effect of generic entry",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "629606b2-3fbe-4791-92e9-a81891a5590d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.71
      },
      "kind": "list",
      "text": "Pro-Forma For Acquisitions (Assumes acquired companies were purchased at the beginning of the prior reporting period)\n3) Including the effect of generic entry\n4) Excluding the effect of generic entry",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e9c4cf8-19be-43ee-ad97-19e583f16465",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.32
      },
      "kind": "paragraph",
      "text": "Valeant provides detailed organic growth transparency, reporting growth in four different ways to assist investors in valuing different components of the business",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2615a972-b703-48ba-884b-45031c55a519",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Organic Revenue Growth Disclosure",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2059cc4-a679-4b5e-b9cd-faaea832c1e0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 50,
      "from": 40,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "3fdb7ddf-ff36-442b-a6da-1c201a07a6a6",
      "evidence": "Discussion of traditional pharma R&D model and Valeant's advantages",
      "position": 1,
      "objective": "Highlighting the cost of inaction in traditional pharma R&D",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}